In this article (Clin Cancer Res 2012;18:2184–98), which was published in the April 15, 2012, issue of Clinical Cancer Research (1), the authors regret failing to fully acknowledge the funding sources for this work. The information that should have been included is as follows:

The research in this article was funded by grants from the Valvano Foundation for Cancer Research (A. Richmond and J.A. Sosman); by a VA Merit Award (A. Richmond) and VA Research Career Scientist Award (A. Richmond) from the Department of Veterans Affairs; by NIH grants CA116021 (A. Richmond), 5P30CA068485 (J. Pietenpol), T32HL07751(T. Sobolik-Delmaire), T32 119925 (O.E. Hawkins), K12-CA090625 (A.E. Vilgelm), and NIH K12 GM068543 Institutional Research and Academic Career Development Award (R.C. Splittgerber); and the National Center for Advancing Translational Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

1.
Su
Y
,
Vilgelm
AE
,
Kelley
MC
,
Hawkins
OE
,
Liu
Y
,
Boyd
KL
, et al
RAF265 inhibits the growth of advanced human melanoma tumors
.
Clin Cancer Res
2012
;
18
:
2184
98
.